Rivastigmine Transdermal Patches Market
Rivastigmine Transdermal Patches Market Size, Share & Trends Analysis Report, By Type (4.6mg/24hr, 9.5mg/24hr, and 13.3 mg/24hr), By Application (Alzheimer’s Disease, Parkinson’s Disease, and Others), Forecast Period (2022-2028) Update Available - Forecast 2024-2030
Rivastigmine transdermal patches market is anticipated to grow at a significant CAGR of 6.5% during the forecast period. According to the World Health Organization (WHO) report named Neurological disorders: Public health challenges, around 24 million people are suffering from Alzheimer's disease and other dementias. According to Parkison’s Foundation, there are around 10 million people suffering from Parkinson’s Disease. The growing prevalence of chronic diseases such as Alzheimer’s and Parkison’s are driving the demand for rivastigmine transdermal patches, which is used as a cholinesterase inhibitor to improves the function of nerve cells in the brain. Further, it has a high tolerability profile, allowing patients to achieve optimal therapeutic doses and providing potential advantages over oral cholinesterase inhibitors. This, in turn, is driving the growth of the global rivastigmine transdermal patches market.
Segmental Outlook
The global rivastigmine transdermal patches market is segmented based on the type and application. Based on the type, the market is segmented into 4.6mg/24hr, 9.5mg/24hr, and 13.3 mg/24hr. Based on the application, the market is segmented into Alzheimer's disease, Parkinson’s disease, and others. The above-mentioned segments can be customized as per the requirements.
Alzheimer's Disease to Witness Significant Share in the Market During the Forecast Period.
The growing prevalence of Alzheimer’s disease globally and the growing preference for rivastigmine transdermal patches to deliver medicines to non-compliant patients, and patients experiencing side effects from oral drugs are primary factors for the rising demand for rivastigmine transdermal patches for the treatment of Alzheimer's disease.
Regional Outlook
The global rivastigmine transdermal patches market is further segmented based on geography including North America (the US and Canada), Europe (UK, Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East &Africa and Latin America). North American region holds a potential share in the market. The presence of key players and the rising prevalence of neurological disorders are some factors accelerating the market growth in the region. However, Asia Pacific is anticipated to register the highest growth during the forecast period. The expansion of the pharmaceutical industry and rising launches of rivastigmine transdermal patches are some key factors driving the market growth in the region. For instance, in December 2021, Luye Pharma signed an agreement with Changchun GeneScience Pharmaceutical Co., Ltd. to expand the regional presence of Its newly launched rivastigmine transdermal patch twice-weekly patch in China.
Global Rivastigmine Transdermal Patches Market Growth, by Region 2022-2028
Market Players Outlook
The major companies serving the global rivastigmine transdermal patches market include Amneal Pharmaceuticals Inc., Luye Pharma Group, Novartis International AG, Ono Pharmaceutical Co., Ltd, and Zydus Healthcare Ltd. The market players are contributing to the market growth by the adoption of various strategies including mergers and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in October 2021, Acino and Aspen Pharmacare Holdings Limited and its subsidiaries signed an agreement for Acino to acquire six South African prescription medicines for over $105.8 million. The acquisition will further strengthen Acino’s footprint in South Africa by expanding its offering in these important therapeutic segments.
Further, in March 2019, Amneal Pharmaceuticals, Inc. declared that it has launched its generic version of Exelon Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval for its Rivastigmine Transdermal System in January 2019 and has received final approval on 10 Abbreviated New Drug Applications this year.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global rivastigmine transdermal patches market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Amneal Pharmaceuticals Inc.
3.1.1.1. Overview
3.1.1.2. Financial Analysis
3.1.1.3. SWOT Analysis
3.1.1.4. Recent Developments
3.1.2. Luye Pharma Group
3.1.2.1. Overview
3.1.2.2. Financial Analysis
3.1.2.3. SWOT Analysis
3.1.2.4. Recent Developments
3.1.3. Novartis International AG
3.1.3.1. Overview
3.1.3.2. Financial Analysis
3.1.3.3. SWOT Analysis
3.1.3.4. Recent Developments
3.1.4. Ono Pharmaceutical Co., Ltd.
3.1.4.1. Overview
3.1.4.2. Financial Analysis
3.1.4.3. SWOT Analysis
3.1.4.4. Recent Developments
3.1.5. Zydus Healthcare Ltd.
3.1.5.1. Overview
3.1.5.2. Financial Analysis
3.1.5.3. SWOT Analysis
3.1.5.4. Recent Developments
3.2. Key Strategy Analysis
4. Market Segmentation
4.1. Global Rivastigmine Transdermal Patches Market by Type
4.1.1. 4.6mg/24hr
4.1.2. 9.5mg/24hr
4.1.3. 13.3 mg/24hr
4.2. Global Rivastigmine Transdermal Patches Market by Application
4.2.1. Alzheimer’s Disease
4.2.2. Parkinson’s Disease
4.2.3. Others
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. AbbVie Inc.
6.2. Acino International AG
6.3. Alvogen
6.4. Amneal Pharmaceuticals LLC.
6.5. Mylan N.V.
6.6. NorthStar Rx LLC
6.7. SinSin Pharmaceutical Co., Ltd.
6.8. Sparsha Pharma International Pvt Ltd.
1. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 4.6MG/24HR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 9.5MG/24HR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 13.3 MG/24HR MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
6. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR ALZHEIMER’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
7. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR PARKINSON’S DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR OTHER APPLICATIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
10. NORTH AMERICAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
11. NORTH AMERICAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
12. NORTH AMERICAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
13. EUROPEAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
14. EUROPEAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
15. EUROPEAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
16. ASIA-PACIFIC RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
17. ASIA-PACIFIC RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
18. ASIA-PACIFIC RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
19. REST OF THE WORLD RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
20. REST OF THE WORLD RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
21. REST OF THE WORLD RIVASTIGMINE TRANSDERMAL PATCHES MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2021-2028 ($ MILLION)
1. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET SHARE BY TYPE, 2021 VS 2028 (%)
2. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 4.6MG/24HR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
3. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 9.5MG/24HR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
4. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR 13.3 MG/24HR MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
5. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET SHARE BY APPLICATION, 2021 VS 2028 (%)
6. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR ALZHEIMER’S DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR PARKINSON’S DISEASE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES FOR OTHER APPLICATIONS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL RIVASTIGMINE TRANSDERMAL PATCHES MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
10. US RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
11. CANADA RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
12. UK RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
13. FRANCE RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
14. GERMANY RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
15. ITALY RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
16. SPAIN RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
17. REST OF EUROPE RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
18. INDIA RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
19. CHINA RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
20. JAPAN RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
21. SOUTH KOREA RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
22. REST OF ASIA-PACIFIC RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
23. REST OF THE WORLD RIVASTIGMINE TRANSDERMAL PATCHES MARKET SIZE, 2021-2028 ($ MILLION)
